0000950170-25-075175 | 10-Q | XBRL Viewer | Neuphoria Therapeutics INC

Print Document

The Company and Basis of Presentation (Details) - Schedule of Company’s Entity Structure at the End of the Reporting Period	9 Months Ended
	Mar. 31, 2025
Neuphoria Therapeutics Inc. [Member]
Schedule of Company's Entity Structure at the End of the Reporting Period [Line Items]
Entity	Parent
Country of Incorporation	United States
Bionomics Limited [Member]
Schedule of Company's Entity Structure at the End of the Reporting Period [Line Items]
Entity	Subsidiary
Country of Incorporation	Australia
Bionomics, Inc. [Member]
Schedule of Company's Entity Structure at the End of the Reporting Period [Line Items]
Entity	Subsidiary
Country of Incorporation	United States

Share Based Compensation

9 Months Ended

Mar. 31, 2025

Share Based Compensation [Abstract]

Share Based Compensation

Note 9. Share Based Compensation

In December 2024, Neuphoria adopted its 2024 Equity Incentive Plan (“2024 Plan”). The maximum number of shares of common stock of the Company that are available for issuance under the 2024 Plan is 1,000,000 shares. On December 24, 2024, our predecessor entity, Bionomics Limited, effected a redomiciliation through a scheme of arrangement under Australian law whereby and following which Neuphoria became the successor entity to Bionomics. As a result of the redomiciliation, Neuphoria issued certain options to acquire shares of common stock in Neuphoria to holders of options to acquire shares in Bionomics (“Bionomics Options”) in exchange for their Bionomics Options. The structure of equity awards is under the active review of the Compensation Committee to ensure it meets good corporate practice for a company of our size, nature and company lifecycle. The Committee may, from time to time, grant Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Stock Bonus Awards and/or Performance Awards to one or more Eligible Persons. At March 31, 2025 there were 949,146 shares available for grant under the 2024 Plan.

Equity awards for executives and employees were previously provided by a combination of equity plans that may include the:

•

Employee Share Plan (the “A$1,000 Plan”);

•

Employee Share Option Plan (“ESOP”); and

•

Employee Equity Plan (“EEP”).

Participation in these plans was at our board of directors’ discretion and no individual has an ongoing contractual right to participate in a plan or to receive any guaranteed benefits. For key appointments, an initial allocation of equity was offered as a component of the recipients initial employment agreement.

The following describes the material terms of each of the historic plans.

Employee Share Plan

The objective of the A$1,000 Plan is to assist Management in the attraction and retention of employees, and to provide encouragement to become shareholders. An annual allocation of up to A$1,000 of shares may be granted and taxed on a concessional basis. No shares were issued to employees under the A$1,000 Plan during the nine months ended March 31, 2025 and 2024, respectively.

The Bionomics Employee Equity Plan and Bionomics Employee Share Option Plan

The EEP replaced the ESOP at the Annual General Meeting held December 2, 2021.

The EEP was last amended on October 31, 2021 to provide the Company with increased flexibility to settle EEP awards offered or granted to non-Australian employees and directors by enabling it to offer and grant EEP awards that may be settled in American Depository Shares (“ADS”) (at a number of ADSs that represents the appropriate number of Ordinary Shares offered or granted under the award). In addition, the amendment permits the Company to (i) determine any monetary amounts and accept payments related to the EEP or awards issued thereunder in United States dollars (or any other currency the Board deems acceptable), (ii) impose terms and conditions on the EEP or awards issued thereunder to comply with the securities and tax laws of the United States (or any other jurisdiction the Board deems appropriate), and (iii) take any other steps the Board deems necessary or desirable to settle EEP awards in ADSs.

Share-based compensation benefits have been provided to employees via the Employee Equity Plan, with the exception of share options issued to the Executive Chairman and the Chief Executive Officer which were each approved by shareholders at the General Meeting held in February 2023.

Staff eligible to participate in the plan are those who have been a full-time or part-time employee of the Company for a period of not less than six months or are members of the Board of Directors. Options are granted under the plan for no consideration and vest equally over five years, or when vesting conditions are achieved, unless they are bonus options which vest immediately. The amounts disclosed as remuneration relating to options are the assessed fair values at grant date of those options allocated equally over the period from grant date to vesting date.

The following table summarizes employee and non-employee share option activity for the nine months ended March 31, 2025:


	Number of Options (1)			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(in years)
Outstanding as of June 30, 2024		51,127		$	158.52		4.18		-
Lapsed		(273	)	$	445.96		—		-
Outstanding as of March 31, 2025		50,854		$	157.09		3.46		-
Options exercisable as of March 31, 2025		44,601		$	172.38		3.11		-

(1) The rollforward of the Number of Options has been corrected to reflect the proper number of lapsed instruments incurred during the nine months ended March 31, 2025 as compared to the information previously reported for the three months ended September 30, 2024. There was no impact to share-based compensation expense due to this corrected disclosure.

As of March 31, 2025, there was approximately $0.1 million of unrecognized compensation cost related to unvested employee share option awards outstanding, which is expected to be recognized as expense over a weighted average period of 0.88 years.

In determining the fair value of the share-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

During the three months ended March 31, 2025 and 2024, the Company recognized total share-based compensation expense of less than $0.1 million during each period, respectively.

During the nine months ended March 31, 2025 and 2024, the Company recognized total share-based compensation expense of less than $0.1 million and $0.9 million, respectively.

Substantially all of the share-based compensation expense was recorded as general and administrative expense in all periods. There were no equity awards issued during the nine months ended March 31, 2025.

Leases

9 Months Ended

Mar. 31, 2025

Leases [Abstract]

Leases

Note 5. Leases

In June 2021, the Company entered into a 5-year lease agreement (the “Greenhill Lease”) for its Australian facility located in Dulwich, South Australia. The initial term of the lease expires in May 2026.

The Greenhill Lease requires monthly lease payments that are subject to annual increases of 3% throughout the lease term. The lease also includes two renewal options, at the election of the Company, to renew or extend the lease for additional terms of one year each. These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these

leases as the Company did not consider it reasonably certain it would exercise the options. Variable lease expense for the premises primarily consists of common area maintenance and other operating costs.

The following table summarizes the Company’s recognition of the Greenhill Lease including the remaining lease payments through the end of the expected lease term:


	March 31,
	2025
Remainder of 2025	$	30,612
2026		114,663
Remaining lease payments		145,275
Less: effect of discounting		(4,215	)
Present value of lease liability	$	141,060

Current operating lease liabilities	$	121,738
Non-current operating lease liabilities		19,322
Total	$	141,060

The discount rate associated with the Company’s operating lease is 3.5% and the weighted average remaining lease term is approximately 1.2 years.

The following table summarizes the effect of lease costs in the Company’s condensed consolidated statements of operations and other comprehensive income (loss):


	Three Months Ended March 31,				Nine Months Ended March 31,
	2025		2024		2025		2024
Operating lease costs
Research and development	$	15,868	$	15,218	$	44,148	$	45,902
General and administrative		15,921		16,945		49,727		50,859
Total	$	31,789	$	32,163	$	93,875	$	96,761

Capital stock	9 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]
Capital stock	Note 11. Capital stock Under the Certificate of Incorporation, Neuphoria is authorized to issue up to 30,000,000 shares of common stock and 3,000,000 shares of preferred stock, par value $0.00001 per share. Common Stock Voting Rights. The holders of our common stock are entitled to one vote per share on all matters on which stockholders are generally entitled to vote; provided, however, that, except as otherwise required by law, holders of common stock, as such, are not entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation. Holders of our common stock do not have cumulative voting rights in the election of directors. Accordingly, the holders of a majority of the combined voting power of our common stock could, if they so choose, elect all the directors. Dividends. Subject to the rights of the holders of any outstanding series of preferred stock, holders of common stock are entitled to receive any dividends to the extent permitted by law when, as and if declared by our board of directors. Liquidation. Upon the dissolution, liquidation, or winding up of Neuphoria, subject to the rights of the holders of any outstanding series of preferred stock, the holders of shares of common stock are entitled to receive the assets of Neuphoria available for distribution to its stockholders ratably in proportion to the number of shares held by them. During the nine months ended March 31, 2025, the Company issued 524,705 shares of common stock to Armistice Capital upon exercise of pre-funded warrants through October 2024. Authorized but Unissued Preferred Stock Unless required by law or by any stock exchange on which our common stock may be listed, the authorized shares of preferred stock will be available for issuance without further action by our stockholders. Delaware law does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of Nasdaq, which apply as long as our common stock is listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the combined voting power of our common stock if issued at a discount to the market price of the common stock. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions, and employee benefit plans. Our Certificate of Incorporation authorizes our board of directors to establish the number of shares to be included in each series of preferred stock, and to fix the designation, powers, preferences, relative participation, optional or other rights, and the qualifications, limitations or restrictions, of the shares of each series of preferred stock. Our board of directors is also able to increase or decrease the number of authorized shares of any series of preferred stock (but not below the number of shares of that series of preferred stock then outstanding) without any further vote or action by the stockholders.

Capital stock

9 Months Ended

Mar. 31, 2025

Stockholders' Equity Note [Abstract]

Capital stock

Note 11. Capital stock

Under the Certificate of Incorporation, Neuphoria is authorized to issue up to 30,000,000 shares of common stock and
3,000,000 shares of preferred stock, par value $0.00001 per share.

Common Stock

Voting Rights. The holders of our common stock are entitled to one vote per share on all matters on which stockholders are generally entitled to vote; provided, however, that, except as otherwise required by law, holders of common stock, as such, are not entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation. Holders of our common stock do not have cumulative voting rights in the election of directors. Accordingly, the holders of a majority of the combined voting power of our common stock could, if they so choose, elect all the directors.

Dividends. Subject to the rights of the holders of any outstanding series of preferred stock, holders of common stock are entitled to receive any dividends to the extent permitted by law when, as and if declared by our board of directors.

Liquidation. Upon the dissolution, liquidation, or winding up of Neuphoria, subject to the rights of the holders of any outstanding series of preferred stock, the holders of shares of common stock are entitled to receive the assets of Neuphoria available for distribution to its stockholders ratably in proportion to the number of shares held by them.

During the nine months ended March 31, 2025, the Company issued 524,705 shares of common stock to Armistice Capital upon exercise of pre-funded warrants through October 2024.

Authorized but Unissued Preferred Stock

Unless required by law or by any stock exchange on which our common stock may be listed, the authorized shares of preferred stock will be available for issuance without further action by our stockholders. Delaware law does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of Nasdaq, which apply as long as our common stock is listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the combined voting power of our common stock if issued at a discount to the market price of the common stock. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions, and employee benefit plans.

Our Certificate of Incorporation authorizes our board of directors to establish the number of shares to be included in each series of preferred stock, and to fix the designation, powers, preferences, relative participation, optional or other rights, and the qualifications, limitations or restrictions, of the shares of each series of preferred stock. Our board of directors is also able to increase or decrease the number of authorized shares of any series of preferred stock (but not below the number of shares of that series of preferred stock then outstanding) without any further vote or action by the stockholders.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Share Based Compensation (Details) $ in Millions	3 Months Ended		9 Months Ended
Share Based Compensation (Details) $ in Millions	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2025 AUD ($) shares	Mar. 31, 2025 USD ($) shares	Mar. 31, 2024 USD ($) shares	Mar. 31, 2025 USD ($) shares	Dec. 31, 2024 shares
Share Based Compensation [Line Items]
Employee share plan			$ 1,000
Vesting period			5 years	5 years
Unrecognized compensation cost (in Dollars)						$ 0.1
Weighted average period			10 months 17 days	10 months 17 days
Equity awards issued during period \| shares			0	0
2024 Equity Incentive Plan [Member]
Share Based Compensation [Line Items]
Number of shares available for grant \| shares			949,146			949,146
Employee Share A Plan [Member]
Share Based Compensation [Line Items]
Employee share plan			$ 1,000
Employee Share Plan [Member]
Share Based Compensation [Line Items]
Employee share plan			1,000
Annual allocation			$ 1,000
Share issued (in Shares) \| shares
Maximum [Member]
Share Based Compensation [Line Items]
Recognized total stock-based compensation expense (in Dollars)	$ 0.1	$ 0.1		$ 0.1	$ 0.9
Maximum [Member] \| 2024 Equity Incentive Plan [Member]
Share Based Compensation [Line Items]
Number of shares available for issuance \| shares							1,000,000

Immaterial Correction of Prior Quarter Error - Summary of Immaterial Corrections to Previously Reported Financial Statements (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2024	Mar. 31, 2025	Mar. 31, 2024	Jun. 30, 2024
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued expenses and other current liabilities	$ 684,989	$ 793,881		$ 793,881	$ 684,989		$ 1,463,421
Accumulated other comprehensive loss, net of tax	(3,912,465)	(3,736,651)		(3,736,651)	(3,912,465)		$ (3,013,595)
Research and development	1,616,011	1,867,420	$ 1,198,546	3,768,323	5,253,953	$ 6,321,691
General and administrative	$ 1,406,796	2,828,176	$ 1,195,485	4,495,000	$ 5,702,807	$ 6,092,809
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued expenses and other current liabilities		484,515		484,515
Accumulated other comprehensive loss, net of tax		(3,716,647)		(3,716,647)
Research and development		1,737,039		3,637,942
General and administrative		2,629,187		4,296,011
Correction [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued expenses and other current liabilities		309,366		309,366
Accumulated other comprehensive loss, net of tax		(20,004)		(20,004)
Research and development		130,381		130,381
General and administrative		$ 198,989		$ 198,989

- Definition

Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Intangible Assets (Tables)

9 Months Ended

Mar. 31, 2025

Intangible Assets [Abstract]

Schedule of Intellectual Property Capitalized


	Cancer Stem Cell Technology			Kv1.3 Compounds (1)			MultiCore (1)			VDA Compounds (1)
Carrying amount at June 30, 2024	$	5,467,522		$	-		$	-		$	-
Amortization expense		(497,048	)		-			-			-
Carrying amount at March 31, 2025	$	4,970,474		$	-		$	-		$	-

Carrying amount at June 30, 2023	$	6,130,253		$	1,057,835		$	865,664		$	1,561,248
Amortization expense		(497,048	)		(1,057,835	)		(865,664	)		(1,561,248	)
Carrying amount at March 31, 2024	$	5,633,205		$	-		$	-		$	-

(1) As of June 30, 2024, the KV1.3 compound, VDA compound, MultiCore technology intangible assets have been derecognized as no future economic benefits are expected from their use or disposition.

Contingent Consideration (Details) - USD ($) $ in Millions	Mar. 31, 2025	Mar. 31, 2024
Contingent Consideration [Abstract]
Liability	$ (0.1)	$ (0.5)

Fair Value Measurement (Details) - Schedule of Company’s Liabilities at Fair Value on a Recurring Basis - USD ($)	Mar. 31, 2025	Jun. 30, 2024
Liabilities:
Accompanying warrants liability	$ 1,887,457	$ 4,657,832
Fair Value, Recurring [Member]
Liabilities:
Contingent consideration	491,785	587,762
Accompanying warrants liability	1,887,457	4,657,832
Total liabilities measured at fair value	2,379,242	5,245,594
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Liabilities:
Contingent consideration
Accompanying warrants liability
Total liabilities measured at fair value
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Liabilities:
Contingent consideration
Accompanying warrants liability
Total liabilities measured at fair value
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Liabilities:
Contingent consideration	491,785	587,762
Accompanying warrants liability	1,887,457	4,657,832
Total liabilities measured at fair value	$ 2,379,242	$ 5,245,594

Subsequent Events

9 Months Ended

Mar. 31, 2025

Subsequent Events [Abstract]

Subsequent Events

Note 19. Subsequent Events

The Company has evaluated subsequent events through May 20, 2025 and has concluded that no events or transactions have occurred that require disclosure in the accompanying condensed consolidated financial statements, except as follows:

Equity Issued Under the At-The-Money ("ATM") Facility

From April 1, 2025 through May 20, 2025 the Company issued 25,321 shares of common stock under its ATM facility for net proceeds of approximately $0.1 million.

Grants made under the 2024 Equity Incentive Plan

On April 16, 2025 the Board granted a total of 33,915 restricted stock units to its members, 27,000 non-qualified stock options to Dr. Spyros Papapetropoulos, and 13,500 non-qualified stock options to a key employee.

There are no other matters or circumstances that have arisen since March 31, 2025 which significantly affect or may significantly affect the results of the operations of the Company.

The Company and Basis of Presentation

9 Months Ended

Mar. 31, 2025

The Company and Basis of Presentation [Abstract]

The Company and Basis of Presentation

Note 1. The Company and Basis of Presentation

Neuphoria Therapeutics Inc. (“the Company”) is a public company incorporated in Delaware. The Company is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing the lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder ("SAD") and for chronic treatment of post-traumatic stress disorder ("PTSD"). BNC210 is a first-of-its-kind, well tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction.

In addition, the Company has a strategic partnership with Merck & Co., Inc. (known as "MSD" outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Our pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.

On October 1, 2024, Bionomics Limited ("Bionomics") announced its intention to redomicile from Australia to the United States via a proposed scheme of arrangement under Australian law between Bionomics and its shareholders (the “Scheme”). Implementation of the Scheme was subject to approval of Bionomics’ shareholders as well as Australian regulatory and court approvals. Bionomics’ ordinary shares, in the form of American Depositary Shares (“ADSs”) traded in the United States since listing on the Nasdaq Global Market ("Nasdaq") in December 2021 until December 23, 2024. The Scheme was approved by Bionomics shareholders and an Australian court in December 2024. On December 23, 2024, shareholders of Bionomics received a proportionate number of shares of common stock in Neuphoria for purposes of the redomiciliation. Neuphoria is the successor issuer to Bionomics and shares of Neuphoria’s common stock commenced trading on Nasdaq on December 24, 2024. All of the issued and outstanding ordinary shares of Bionomics were exchanged for newly issued shares of common stock of Neuphoria, on the basis of one share of common stock for every 2,160 ordinary share. Shareholders of Bionomics’ ADSs (each of which represented 180 ordinary shares) were exchanged for one share of common stock for every 12 ADS held. In addition, as a result of the redomiciliation, Neuphoria issued certain options to acquire shares of common stock in Neuphoria to holders of options to acquire shares in Bionomics (“Bionomics Options”) in exchange for their Bionomics Options and issued a warrant to purchase 1,054,381 shares of common stock in Neuphoria to an institutional investor that held a warrant to purchase 12,652,572 ADSs of Bionomics (“Bionomics Warrant”), in exchange for the Bionomics Warrant.

The issued and outstanding shares and all share and earnings per share amounts of Neuphoria’s common stock as shown in this report have been adjusted in the condensed consolidated financial statements to reflect the redomiciliation as if it had occurred on June 30, 2023.

Details of the Company’s entity structure at the end of the reporting period are as follows (post-redomiciliation):


Name	Entity	Country of Incorporation
Neuphoria Therapeutics Inc.	Parent	United States
Bionomics Limited	Subsidiary	Australia
Bionomics, Inc.	Subsidiary	United States

Liquidity and Going Concern

As of March 31, 2025, the Company had working capital of $15.5 million, an accumulated deficit of $169.5 million, and cash and cash equivalents of $17.0 million. The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and non-clinical testing, and commercialization of the Company’s products will require significant additional financing.

The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology, and market acceptance of the Company’s products. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company’s future success.

In accordance with ASC 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company earned net income of $11.3 million and $8.5 million for the three and nine months ended March 31, 2025 resulting from the receipt of milestone payments associated with our research

collaboration and licensing agreements (Note 12) and incurred a net loss of $15.5 million for the year ended June 30, 2024. The Company also generated $3.7 million of cash for operating activities during the nine months ended March 31, 2025.

Based upon the Company’s current operating plans, the Company believes that its existing cash and cash equivalents will be sufficient to continue funding its development activities into the first quarter of fiscal year 2027, which is more than twelve months from the date these condensed consolidated financial statements are issued. Consequently, management has determined there is no substantial doubt regarding the Company's ability to continue as a going concern for the twelve month period from the date these financial statements are issued.

The Company has based projections of operating capital requirements on the current operating plan, which includes several assumptions that may prove to be incorrect, and the Company may use all available capital resources sooner than the Company expects. The accompanying condensed consolidated financial statements do not include adjustments that might result from the outcome of uncertainties and assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. If the Company is unable to obtain sufficient funding on acceptable terms, it could be forced to delay, reduce or eliminate some or all its research and development programs or commercialization activities, which could materially adversely affect its business prospects or its ability to continue operations.

Basis of Presentation

In December 2024, a Scheme was approved by Bionomics shareholders and an Australian court, and, on December 23, 2024, shareholders of Bionomics received a proportionate number of shares of common stock in Neuphoria for purposes of the redomiciliation and Bionomics became a wholly-owned subsidiary of Neuphoria, which is the new parent company of Bionomics. The historical financial statements of Bionomics became the historical financial statements of the combined company upon consummation of the redomiciliation. As a result, the financial statements included in this report reflect (i) the historical operating results of Bionomics, its subsidiaries, and Neuphoria beginning July 1, 2024; (ii) the combined results of the Company, Bionomics, and subsidiaries following the formation of Neuphoria; and (iii) the Company’s equity structure for all periods presented, including adjusting the issued and outstanding shares of common stock to reflect the redomiciliation as if it had occurred on June 30, 2023.

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP” or “GAAP”) and include the accounts of our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of June 30, 2024 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The accompanying condensed consolidated financial statements, as of March 31, 2025 and for the three and nine months ended March 31, 2025, are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures are adequate to make the information presented not misleading.

These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended June 30, 2024 included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 filed with the SEC on September 30, 2024. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, as necessary for the fair statement of the Company’s financial position as of March 31, 2025, results of its operations for the three and nine months ended March 31, 2025, shareholders’ equity for the three and nine months ended March 31, 2025, and cash flows for the nine months ended March 31, 2025, have been made. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results of operations to be expected for the year ending June 30, 2025.

The Company was previously classified as a foreign private issuer (“FPI”); however, as of December 31, 2023 (the "Measurement Date") the Company determined that it no longer satisfied the criteria to be considered an FPI. As such, beginning on July 1, 2024, the Company was required to begin utilizing the SEC’s domestic reporting forms and apply U.S. GAAP as its accounting framework. There were no material adjustments required as a result of this adjustment to retrospectively apply U.S. GAAP to the accompanying condensed consolidated financial statements. Another requirement of utilizing the SEC’s domestic reporting forms is a requirement to use the U.S. dollar as the reporting currency. These consolidated financial statements reflect the change in reporting currency to the U.S. dollar applied retrospectively. References to “$” are U.S dollars and references to “A$” are to Australian dollars.

The presentation of shareholders' equity in the consolidated balance sheets at June 30, 2023, as previously reported under International Financial Reporting Standards ("IFRS") was reclassified to comply with the presentation under U.S. GAAP.

All share and earnings per share amounts presented herein reflect the impact of the redomiciliation as if it had taken effect on June 30, 2023.

Related Party Transactions (Details) - USD ($)	3 Months Ended	9 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 31, 2025	Mar. 31, 2025
Related Party Transactions [Line Items]
Monthly fee		$ 15,000
WG Partners LLP [Member]
Related Party Transactions [Line Items]
Service paid	$ 59,841	$ 79,206

Fair Value Measurement (Details) - Schedule of Fair Value was Determined by Level 3 Inputs - USD ($)	9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Contingent Consideration in a Business Combination [Member]
Schedule of Fair Value was Determined by Level 3 Inputs [Line Items]
Balance at beginning	$ 587,762	$ 2,456,199
Payment of milestone obligation to Eclipse	(133,080)
Change in fair value, net of foreign currency effect	37,103	535,572
Change in fair value		535,572
Balance at ending	491,785	$ 2,991,771
Freestanding Financial Instruments Accompanying Warrant Liability [Member]
Schedule of Fair Value was Determined by Level 3 Inputs [Line Items]
Balance at beginning	4,657,832
Change in fair value, net of foreign currency effect	(2,770,375)
Balance at ending	$ 1,887,457

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Mar. 31, 2025

Accrued Expenses and Other Current Liabilities [Abstract]

Schedule of Accrued Expenses

Accrued expenses and other current liabilities consist of the following:


	March 31,		June 30,
	2025		2024
Salary and benefits	$	397,652	$	648,858
Research and development expenses		209,287		134,910
Other		32,994		37,581
EDA Loan		31,400		33,120
Professional and consulting fees		13,656		297,780
Insurance		-		311,172
Total accrued expenses and other current liabilities	$	684,989	$	1,463,421

Net Income (Loss) per Share (Details) - Schedule of Potential Shares of Common Stock - shares	9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Options to Purchase Common Stock [Member]
Schedule of Potential Ordinary Shares [Line Items]
Potential shares of common stock are anti-dilutive	50,854	49,897
Warrants To Purchase Common Stock [Member]
Schedule of Potential Ordinary Shares [Line Items]
Potential shares of common stock are anti-dilutive	1,054,381	1,054,381

Leases (Tables)

9 Months Ended

Mar. 31, 2025

Leases [Abstract]

Schedule of Effect of Lease Costs in our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

The following table summarizes the effect of lease costs in the Company’s condensed consolidated statements of operations and other comprehensive income (loss):


	Three Months Ended March 31,				Nine Months Ended March 31,
	2025		2024		2025		2024
Operating lease costs
Research and development	$	15,868	$	15,218	$	44,148	$	45,902
General and administrative		15,921		16,945		49,727		50,859
Total	$	31,789	$	32,163	$	93,875	$	96,761

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2025	May 16, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Amendment Flag	false
Document Period End Date	Mar. 31, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Entity Registrant Name	Neuphoria Therapeutics Inc.
Entity Central Index Key	0001191070
Securities Act File Number	001-41157
Entity Tax Identification Number	99-3845448
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Address, Address Line One	100 Summit Drive
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	781
Local Phone Number	439-5551
Title of 12(b) Security	Common Stock, $0.00001 par value per share
Trading Symbol	NEUP
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		1,879,962

Warrants (Tables)

9 Months Ended

Mar. 31, 2025

Warrants [Abstract]

Schedule of Warrant Activity

The following table summarizes warrant activity for the nine months ended March 31, 2025:


	Number of Warrants			Weighted Average Exercise Price USD
Balance at June 30, 2024		1,579,086		$	7.92
Exercised		(524,705	)		-
Balance at March 31, 2025		1,054,381		$	11.88

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
Pay vs Performance Disclosure - USD ($)	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2025	Mar. 31, 2024	Jun. 30, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ 11,262,161	$ (1,943,349)	$ (804,787)	$ (2,778,148)	$ (4,554,424)	$ (5,472,568)	$ 8,514,025	$ (12,805,140)	$ (15,500,000)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Accounts Receivable, Non-trade (Details) - Schedule of Accounts Receivable, Non-Trade - USD ($)	Mar. 31, 2025	Jun. 30, 2024
Schedule of Accounts Receivable, Non-Trade [Abstract]
Research and development incentives receivable		$ 96,154
GST receivables	$ 21,684	30,444
Interest receivable	2,908	286
Total accounts receivable, non-trade	$ 24,592	$ 126,884

Capital Stock (Details) - $ / shares	9 Months Ended
Capital Stock (Details) - $ / shares	Mar. 31, 2025	Jun. 30, 2024
Class of Stock [Line Items]
Common stock, shares authorized	30,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	3,000,000
Preferred stock, par value	$ 0.00001
Common stock, voting rights	The holders of our common stock are entitled to one vote per share
ADS [Member]
Class of Stock [Line Items]
Stock issued during period, shares	524,705

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Net Income (Loss) per Share (Details) - Schedule of Compilation of Diluted Earnings Per Share - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2025	Mar. 31, 2024	Jun. 30, 2024
Earnings per share - basic:
Net Income (Loss)	$ 11,262,161	$ (1,943,349)	$ (804,787)	$ (2,778,148)	$ (4,554,424)	$ (5,472,568)	$ 8,514,025	$ (12,805,140)	$ (15,500,000)
Weighted average shares - basic	1,719,073			981,040			1,530,091	842,431
Net income per share - basic	$ 6.55			$ (2.83)			$ 5.56	$ (15.2)
Earnings per share - diluted:
Less: effect of revaluation of accompanying warrant liability							$ (2,770,375)
Net income plus assumed conversion of accompanying warrants	$ 11,262,161						$ 5,743,650
Weighted average shares - diluted	1,719,073			981,040			1,530,091	842,431
Net income per share - diluted	$ 6.55			$ (2.83)			$ 3.75	$ (15.2)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Fair Value Measurement (Tables)

9 Months Ended

Mar. 31, 2025

Fair Value Measurements [Line Items]

Schedule of Company’S Liabilities at Fair Value on a Recurring Basis

The following tables set forth the fair value of the Company’s liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy:


	March 31, 2025
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration	$	-	$	-	$	491,785	$	491,785
Accompanying warrants liability		-		-		1,887,457		1,887,457
Total liabilities measured at fair value	$	-	$	-	$	2,379,242	$	2,379,242


	June 30, 2024
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration	$	-	$	-	$	587,762	$	587,762
Accompanying warrants liability		-		-		4,657,832		4,657,832
Total liabilities measured at fair value	$	-	$	-	$	5,245,594	$	5,245,594

Schedule of Fair Value was Determined by Level 3 Inputs

The following table summarizes contingent consideration activity for the nine months ended March 31, 2025 and 2024:


	Contingent Consideration in a Business Combination
Balance at June 30, 2024	$	587,762
Payment of milestone obligation to Eclipse		(133,080	)
Change in fair value, net of foreign currency effect		37,103
Balance at March 31, 2025	$	491,785

	Contingent Consideration in a Business Combination
Balance at June 30, 2023	$	2,456,199
Change in fair value, net of foreign currency effect		535,572
Balance at March 31, 2024	$	2,991,771

Warrant [Member]

Fair Value Measurements [Line Items]

Schedule of Fair Value was Determined by Level 3 Inputs

The following table summarizes changes in the fair value of the contingent consideration and the accompanying warrants liability, each for which each fair value was determined by Level 3 inputs:


	Contingent Consideration in a Business Combination			Freestanding Financial Instruments Accompanying Warrants Liability
Balance at June 30, 2024	$	587,762		$	4,657,832
Payment of milestone obligation to Eclipse		(133,080	)		-
Change in fair value, net of foreign currency effect		37,103			(2,770,375	)
Balance at March 31, 2025	$	491,785		$	1,887,457


	Contingent Consideration in a Business Combination
Balance at June 30, 2023	$	2,456,199
Change in fair value		535,572
Balance at March 31, 2024	$	2,991,771

Share Based Compensation (Tables)

9 Months Ended

Mar. 31, 2025

Share Based Compensation [Abstract]

Schedule of Summarizes Employee and Non-Employee Stock Option Activity

The following table summarizes employee and non-employee share option activity for the nine months ended March 31, 2025:


	Number of Options (1)			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(in years)
Outstanding as of June 30, 2024		51,127		$	158.52		4.18		-
Lapsed		(273	)	$	445.96		—		-
Outstanding as of March 31, 2025		50,854		$	157.09		3.46		-
Options exercisable as of March 31, 2025		44,601		$	172.38		3.11		-

Contingent Consideration (Tables)

9 Months Ended

Mar. 31, 2025

Contingent Consideration [Abstract]

Summary of Contingent Consideration Activity

The following table summarizes contingent consideration activity for the nine months ended March 31, 2025 and 2024:


	Contingent Consideration in a Business Combination
Balance at June 30, 2024	$	587,762
Payment of milestone obligation to Eclipse		(133,080	)
Change in fair value, net of foreign currency effect		37,103
Balance at March 31, 2025	$	491,785

	Contingent Consideration in a Business Combination
Balance at June 30, 2023	$	2,456,199
Change in fair value, net of foreign currency effect		535,572
Balance at March 31, 2024	$	2,991,771

Accounts Receivable, Non-trade (Tables)

9 Months Ended

Mar. 31, 2025

Accounts Receivable, Non-trade [Abstract]

Schedule of Accounts Receivable, Non-Trade

Accounts receivable, non-trade consist of the following:


	March 31,		June 30,
	2025		2024
Research and development incentives receivable	$	-	$	96,154
GST receivables		21,684		30,444
Interest receivable		2,908		286
Total accounts receivable, non-trade	$	24,592	$	126,884

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2025	Jun. 30, 2024
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.00001	$ 0.00001
Ordinary shares, shares issued	1,853,966	1,103,954
Ordinary shares, shares outstanding	1,853,966	1,103,954

Share Based Compensation (Details) - Schedule of Summarizes Employee and Non-Employee Stock Option Activity

9 Months Ended

12 Months Ended

Mar. 31, 2025

$ / shares

Mar. 31, 2025

USD ($)

Jun. 30, 2024

USD ($)

Mar. 31, 2025

USD ($)

Schedule of Summarizes Employee and Non-Employee Stock Option Activity [Line Items]

Number of Options, Outstanding Beginning Balance | shares

^[1]

51,127

Weighted Average Exercise Price per Share, Outstanding Beginning Balance | $ / shares

$ 158.52

Weighted Average Remaining Contractual Term, Outstanding Ending Balance

3 years 5 months 15 days

4 years 2 months 4 days

Aggregate Intrinsic Value, Outstanding Ending Balance | $

Number of Options, Lapsed | shares

^[1]

(273)

Weighted Average Exercise Price per Share, Lapsed | $ / shares

445.96

Number of Options, Outstanding Ending Balance | shares

^[1]

50,854

51,127

Weighted Average Exercise Price per Share, Outstanding Ending Balance | $ / shares

157.09

Number of Options, Options exercisable | shares

^[1]

44,601

Weighted Average Exercise Price per Share, Options exercisable | $ / shares

$ 172.38

Weighted Average Remaining Contractual Term, Options exercisable

3 years 1 month 9 days

Aggregate Intrinsic Value, Options exercisable | $

[1]

The rollforward of the Number of Options has been corrected to reflect the proper number of lapsed instruments incurred during the nine months ended March 31, 2025 as compared to the information previously reported for the three months ended September 30, 2024. There was no impact to share-based compensation expense due to this corrected disclosure.

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2025
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Revenue Recognition Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: License revenue The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer, and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (“SSP”) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. If an arrangement includes development, regulatory, or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include, but are not limited to, the performance obligations under the Company’s research collaboration and licensing agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates. Summary of Significant Accounting Policies There were no changes to significant accounting policies during the nine months ended March 31, 2025, besides those listed above, as compared to those identified in the fiscal 2024 Annual Report on Form 10-K. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to this new standard. However, given the Company has one reportable segment, this policy is not expected to have a material impact on the Company's consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard but adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements. In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory, employee compensation depreciation, amortization, and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.

Leases (Details)	Mar. 31, 2025	Jun. 30, 2021
Leases [Abstract]
Lease term		5 years
Renew or extend term	1 year
Weighted average remaining lease percentage	3.50%
Weighted average remaining lease term	1 year 2 months 12 days

Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses - USD ($)	Mar. 31, 2025	Dec. 31, 2024	Jun. 30, 2024
Schedule of Accrued Expenses [Abstract]
Salary and benefits	$ 397,652		$ 648,858
Research and development expenses	209,287		134,910
Other	32,994		37,581
EDA Loan	31,400		33,120
Professional and consulting fees	13,656		297,780
Insurance	0		311,172
Total accrued expenses and other current liabilities	$ 684,989	$ 793,881	$ 1,463,421

Net Income (Loss) per Share

9 Months Ended

Mar. 31, 2025

Net Income (Loss) per Share [Abstract]

Net Income (Loss) per Share

Note 14. Net Income (Loss) per Share

The following table details the compilation of diluted earnings per share for the three and nine months ended March 31, 2025:


	Three months ended		Nine Months Ended
	March 31, 2025		March 31, 2025
Earnings per share - basic:
Net Income	$	11,262,161	$	8,514,025
Weighted average shares - basic		1,719,073		1,530,091
Net income per share - basic	$	6.55	$	5.56

Earnings per share - diluted:
Net Income	$	11,262,161	$	8,514,025
Less: effect of revaluation of accompanying warrant liability		—		(2,770,375	)
Net income plus assumed conversion of accompanying warrants	$	11,262,161	$	5,743,650
Weighted average shares - diluted		1,719,073		1,530,091
Net income per share - diluted	$	6.55	$	3.75

The dilutive effect of the accompanying warrants has been excluded in the calculation of weighted-average shares - diluted as required under the treasury stock method, which assumes conversion of the accompanying warrants only for those instruments that are in-the-money at any time during the reporting period. At no time during the three and nine months ended March 31, 2025 were the accompanying warrants in-the-money.

The following potential shares of common stock are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share.


	March 31,
	2025		2024
Options to purchase common stock		50,854		49,897
Warrants to purchase common stock		1,054,381		1,054,381

All share and earnings per share amounts presented above reflect the impact of the redomiciliation as if it had taken effect on July 1, 2023.

Contingent Consideration - Summary of Contingent Consideration Activity (Details) - Contingent Consideration in a Business Combination [Member] - USD ($)	9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Schedule of Company's Liabilities at Fair Value on a Recurring Basis [Line Items]
Balance at beginning	$ 587,762	$ 2,456,199
Payment of milestone obligation to Eclipse	(133,080)
Change in fair value, net of foreign currency effect	37,103	535,572
Balance at ending	$ 491,785	$ 2,991,771

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($)	Total	Common Shares	Stock Subscription Receivable	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Jun. 30, 2023	$ 22,010,563	$ 7		$ 187,554,244	$ (3,058,783)	$ (162,484,905)
Balance (in Shares) at Jun. 30, 2023		679,970
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable	612,538	$ 2	$ (5,648,976)	6,261,512
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable (in Shares)		175,072
Share-based compensation	140,448			140,448
Other comprehensive income (loss)	(63,469)				(63,469)
Net income (loss)	(5,472,568)					(5,472,568)
Balance at Sep. 30, 2023	17,227,512	$ 9	(5,648,976)	193,956,204	(3,122,252)	(167,957,473)
Balance (in Shares) at Sep. 30, 2023		855,042
Balance at Jun. 30, 2023	22,010,563	$ 7		187,554,244	(3,058,783)	(162,484,905)
Balance (in Shares) at Jun. 30, 2023		679,970
Net income (loss)	(12,805,140)
Balance at Mar. 31, 2024	17,945,737	$ 10		196,468,887	(3,233,115)	(175,290,045)
Balance (in Shares) at Mar. 31, 2024		995,913
Balance at Jun. 30, 2023	22,010,563	$ 7		187,554,244	(3,058,783)	(162,484,905)
Balance (in Shares) at Jun. 30, 2023		679,970
Net income (loss)	(15,500,000)
Balance at Jun. 30, 2024	17,490,372	$ 11		198,481,027	(3,013,595)	(177,977,071)
Balance (in Shares) at Jun. 30, 2024		1,103,954
Balance at Sep. 30, 2023	17,227,512	$ 9	(5,648,976)	193,956,204	(3,122,252)	(167,957,473)
Balance (in Shares) at Sep. 30, 2023		855,042
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable	(22,642)		(311,426)	288,784
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable (in Shares)		36,073
Collection of subscription receivable	5,648,976		5,648,976
Share-based compensation	746,936			746,936
Other comprehensive income (loss)	451,085				451,085
Net income (loss)	(4,554,424)					(4,554,424)
Balance at Dec. 31, 2023	19,497,443	$ 9	(311,426)	194,991,924	(2,671,167)	(172,511,897)
Balance (in Shares) at Dec. 31, 2023		891,115
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable	1,436,933	$ 1		1,436,932
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable (in Shares)		104,798
Collection of subscription receivable	311,426		$ 311,426
Share-based compensation	40,031			40,031
Other comprehensive income (loss)	(561,948)				(561,948)
Net income (loss)	(2,778,148)					(2,778,148)
Balance at Mar. 31, 2024	17,945,737	$ 10		196,468,887	(3,233,115)	(175,290,045)
Balance (in Shares) at Mar. 31, 2024		995,913
Balance at Jun. 30, 2024	17,490,372	$ 11		198,481,027	(3,013,595)	(177,977,071)
Balance (in Shares) at Jun. 30, 2024		1,103,954
Exercise of pre-funded ADS warrants	409	$ 3		406
Exercise of pre-funded ADS warrants (in Shares)		339,408
Share issue costs	(227,747)			(227,747)
Share-based compensation	26,736			26,736
Other comprehensive income (loss)	585,381				585,381
Net income (loss)	(804,787)					(804,787)
Balance at Sep. 30, 2024	17,070,364	$ 14		198,280,422	(2,428,214)	(178,781,858)
Balance (in Shares) at Sep. 30, 2024		1,443,362
Balance at Jun. 30, 2024	17,490,372	$ 11		198,481,027	(3,013,595)	(177,977,071)
Balance (in Shares) at Jun. 30, 2024		1,103,954
Net income (loss)	8,514,025
Balance at Mar. 31, 2025	25,997,308	$ 19		199,372,800	(3,912,465)	(169,463,046)
Balance (in Shares) at Mar. 31, 2025		1,853,966
Balance at Sep. 30, 2024	17,070,364	$ 14		198,280,422	(2,428,214)	(178,781,858)
Balance (in Shares) at Sep. 30, 2024		1,443,362
Exercise of pre-funded ADS warrants	220	$ 2		218
Exercise of pre-funded ADS warrants (in Shares)		185,297
Share issue costs	(111,777)			(111,777)
Share-based compensation	20,970			20,970
Other comprehensive income (loss)	(1,288,433)				(1,288,433)
Net income (loss)	(1,943,349)					(1,943,349)
Balance at Dec. 31, 2024	13,747,995	$ 16		198,189,833	(3,716,647)	(180,725,207)
Balance (in Shares) at Dec. 31, 2024		1,628,659
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable	1,162,504	$ 3		1,162,501
Issuance of ADS shares/Common stock in connection with ATM facility, net of issuance costs and stock subscription receivable (in Shares)		225,307
Share-based compensation	20,466			20,466
Other comprehensive income (loss)	(195,818)				(195,818)
Net income (loss)	11,262,161					11,262,161
Balance at Mar. 31, 2025	$ 25,997,308	$ 19		$ 199,372,800	$ (3,912,465)	$ (169,463,046)
Balance (in Shares) at Mar. 31, 2025		1,853,966

The Company and Basis of Presentation (Details)		3 Months Ended						9 Months Ended		12 Months Ended
The Company and Basis of Presentation (Details)	Dec. 24, 2024 shares	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Working capital		$ 15,500,000						$ 15,500,000
Accumulated deficit		(169,463,046)						(169,463,046)		$ (177,977,071)
Cash and cash equivalents		17,044,750			$ 8,426,061			17,044,750	$ 8,426,061	12,608,109
Net losses		$ 11,262,161	$ (1,943,349)	$ (804,787)	$ (2,778,148)	$ (4,554,424)	$ (5,472,568)	8,514,025	(12,805,140)	$ (15,500,000)
Cash for operating activities								$ 3,662,302	$ (11,669,987)
ADS [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion ratio description								one share of common stock for every 12 ADS
Conversion ratio	15
Number of warrants to be issued (in Shares) \| shares	12,652,572
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion ratio description								one share of common stock for every 2,160 ordinary share
Conversion ratio	0.000463
Number of warrants to be issued (in Shares) \| shares	1,054,381

Commitments and Contingencies

9 Months Ended

Mar. 31, 2025

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 17. Commitments and Contingencies

Ironwood Pharmaceuticals, Inc.

In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.

Severance Obligation

The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $787,500.

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.Y.Q4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.Y.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/450-20/tableOfContent

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/450-30/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

License Revenue (Details) $ in Millions	Mar. 31, 2025 USD ($)	Mar. 14, 2025 USD ($)	Oct. 31, 2024 AUD ($)	Nov. 30, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other change in transaction price		$ 0
Merck & Co., Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment	$ 15,000,000
Merck & Co., Inc. [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Eligible to receive development, regulatory milestone payments	$ 450,000,000
Carina Biotech [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Eligible to receive development, regulatory milestone payments				$ 3,000,000
Milestone payment			$ 1

Warrants (Details) - $ / shares	Mar. 31, 2025	Dec. 24, 2024
Warrant [Member]
Warrants [Line Items]
Vested and exercisable	1,054,381
weighted average remaining contractual life	4 years 2 months 4 days
ADS [Member]
Warrants [Line Items]
Number of warrants to be issued (in Shares)		12,652,572
ADS [Member] \| Maximum [Member]
Warrants [Line Items]
Number of warrants to be issued (in Shares)		12,652,572
Common Stock [Member]
Warrants [Line Items]
Number of warrants to be issued (in Shares)		1,054,381
price per share		$ 11.88
Common Stock [Member] \| Maximum [Member]
Warrants [Line Items]
Number of warrants to be issued (in Shares)		1,054,381

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Immaterial Correction of Prior Quarter Error (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development	$ 1,616,011	$ 1,867,420	$ 1,198,546	$ 3,768,323	$ 5,253,953	$ 6,321,691
General and administrative	$ 1,406,796	2,828,176	$ 1,195,485	4,495,000	$ 5,702,807	$ 6,092,809
Error Correction, Previously Immaterial [true false]	true				true
Error Correction Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development		300,000		300,000
General and administrative		$ 300,000		$ 300,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2025
Summary of Significant Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: License revenue The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer, and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (“SSP”) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. If an arrangement includes development, regulatory, or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method.
Use of Estimates	Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include, but are not limited to, the performance obligations under the Company’s research collaboration and licensing agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates.

Immaterial Correction of Prior Quarter Error

9 Months Ended

Mar. 31, 2025

Accounting Changes and Error Corrections [Abstract]

Immaterial Correction of Prior Quarter Error

Note 18. Immaterial Correction of Prior Quarter Error

During the three months ended March 31, 2025, the Company identified an error in the financial statements for the three and six months ended December 31, 2024, where it did not record approximately $0.3 million in general and administrative and research and development expenses during the periods then ended. The Company recorded the expenses during the three months ended March 31, 2025, effectively correcting the cutoff error on a year-to-date basis. The Company assessed the materiality of the cut-off error in accordance with applicable accounting guidance. The effect of the error had no impact on the Company’s financial statements for the nine months ended March 31, 2025.

The financial reporting period affected by this error includes the Company’s previously reported unaudited condensed consolidated financial statements as of, and for the three and six months ended, December 31, 2024. As noted above, the Company effectively corrected the error during the three months ended March 31, 2025, as presented in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company considered the impact of the prior December 31, 2024 quarterly period error and impact of correcting the error in the current March 31, 2025 quarterly period to be immaterial. A summary of the immaterial corrections to the Company’s previously reported unaudited condensed consolidated financial statements are as follows:


	As of December 31, 2024
	As Reported			Correction			As Corrected
Accrued expenses and other current liabilities	$	484,515		$	309,366		$	793,881
Accumulated other comprehensive loss, net of tax		(3,716,647	)		(20,004	)		(3,736,651	)

	Three Months Ended December 31, 2024
	As Reported			Correction			As Corrected
Research and development	$	1,737,039		$	130,381		$	1,867,420
General and administrative		2,629,187			198,989			2,828,176

	Six Months Ended December 31, 2024
	As Reported			Correction			As Corrected
Research and development	$	3,637,942		$	130,381		$	3,768,323
General and administrative		4,296,011			198,989			4,495,000

Subsequent Events (Details) - USD ($)		2 Months Ended	9 Months Ended
Subsequent Events (Details) - USD ($)	Apr. 16, 2025	May 20, 2025	Mar. 31, 2025	Mar. 31, 2024	Jun. 30, 2024
Subsequent Events [Line Items]
Common stock shares issued under ATM facility			1,853,966		1,103,954
Net proceeds			$ 823,601	$ 7,987,228
Subsequent Event [Member]
Subsequent Events [Line Items]
Common stock shares issued under ATM facility		25,321
Net proceeds		$ 100,000
Subsequent Event [Member] \| 2024 Equity Incentive Plan [Member] \| Dr. Spyros Papapetropoulos [Member]
Subsequent Events [Line Items]
Non-qualified stock options	27,000
Subsequent Event [Member] \| 2024 Equity Incentive Plan [Member] \| Key Employee [Member]
Subsequent Events [Line Items]
Non-qualified stock options	13,500
Subsequent Event [Member] \| 2024 Equity Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Subsequent Events [Line Items]
Granted	33,915

Fair Value Measurement

9 Months Ended

Mar. 31, 2025

Fair Value Measurement [Abstract]

Fair Value Measurement

Note 3. Fair Value Measurement

The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company’s liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy:


	March 31, 2025
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration	$	-	$	-	$	491,785	$	491,785
Accompanying warrants liability		-		-		1,887,457		1,887,457
Total liabilities measured at fair value	$	-	$	-	$	2,379,242	$	2,379,242


	June 30, 2024
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration	$	-	$	-	$	587,762	$	587,762
Accompanying warrants liability		-		-		4,657,832		4,657,832
Total liabilities measured at fair value	$	-	$	-	$	5,245,594	$	5,245,594

The Company has no financial assets that are measured at fair value. The liabilities measured at fair value at March 31, 2025 and June 30, 2024 are contingent consideration and the accompanying warrant liability (also referred to herein as the Bionomics Warrant). The value of financial assets and other financial liabilities approximate their fair value. The following table gives information about how the fair value of the financial liability is determined.

The accompanying warrants liability relates to the Company’s issuance of accompanying warrants in conjunction with a Private Placement in June 2024. The fair value of the accompanying warrants liability was based on valuations that required inputs that were both significant to the fair value measurement and unobservable. This approach resulted in a classification of the accompanying warrants liability as Level 3 of the fair value hierarchy. See Note 16 for additional disclosure related to contingent consideration.

The following table summarizes changes in the fair value of the contingent consideration and the accompanying warrants liability, each for which each fair value was determined by Level 3 inputs:


	Contingent Consideration in a Business Combination			Freestanding Financial Instruments Accompanying Warrants Liability
Balance at June 30, 2024	$	587,762		$	4,657,832
Payment of milestone obligation to Eclipse		(133,080	)		-
Change in fair value, net of foreign currency effect		37,103			(2,770,375	)
Balance at March 31, 2025	$	491,785		$	1,887,457


	Contingent Consideration in a Business Combination
Balance at June 30, 2023	$	2,456,199
Change in fair value		535,572
Balance at March 31, 2024	$	2,991,771

The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between levels during the periods presented.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Immaterial Correction of Prior Quarter Error (Tables)

9 Months Ended

Mar. 31, 2025

Accounting Changes and Error Corrections [Abstract]

Summary of Immaterial Corrections to Previously Reported Financial Statements

A summary of the immaterial corrections to the Company’s previously reported unaudited condensed consolidated financial statements are as follows:


	As of December 31, 2024
	As Reported			Correction			As Corrected
Accrued expenses and other current liabilities	$	484,515		$	309,366		$	793,881
Accumulated other comprehensive loss, net of tax		(3,716,647	)		(20,004	)		(3,736,651	)

	Three Months Ended December 31, 2024
	As Reported			Correction			As Corrected
Research and development	$	1,737,039		$	130,381		$	1,867,420
General and administrative		2,629,187			198,989			2,828,176

	Six Months Ended December 31, 2024
	As Reported			Correction			As Corrected
Research and development	$	3,637,942		$	130,381		$	3,768,323
General and administrative		4,296,011			198,989			4,495,000

Intangible Assets (Details)	Mar. 31, 2025
Intangible Assets [Abstract]
Estimated useful	20 years

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2025	Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 0.1	$ 0.1	$ 0.3	$ 0.5	$ 0.4	$ 0.9

Accrued Expenses and Other Current Liabilities

9 Months Ended

Mar. 31, 2025

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Note 8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:


	March 31,		June 30,
	2025		2024
Salary and benefits	$	397,652	$	648,858
Research and development expenses		209,287		134,910
Other		32,994		37,581
EDA Loan		31,400		33,120
Professional and consulting fees		13,656		297,780
Insurance		-		311,172
Total accrued expenses and other current liabilities	$	684,989	$	1,463,421

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2025	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 17,044,750	$ 12,608,109
Accounts receivable, non-trade	24,592	126,884
Prepaid insurance expense	20,897	458,765
Total current assets	17,090,239	13,193,758
Property and equipment, net	1,623	1,994
Intangible assets, net	4,970,474	5,467,522
Operating lease right-of-use assets	125,213	216,975
Restricted cash	74,732	78,826
Goodwill	8,451,038	8,690,018
Total assets	30,713,319	27,649,093
Current liabilities:
Accounts payable	745,336	2,243,662
Accrued expenses and other current liabilities	684,989	1,463,421
Operating lease liability	121,738	121,990
Total current liabilities	1,552,063	3,829,073
Operating lease liability, net of current portion	19,322	117,628
Contingent consideration	491,785	587,762
Deferred tax liability	761,737	963,540
Accompanying warrants liability	1,887,457	4,657,832
Other non-current liabilities	3,647	2,886
Total liabilities	4,716,011	10,158,721
Commitments and contingencies (Note 17)
Shareholders’ equity:
Common stock, $0.00001 par value, 1,853,966 and 1,103,954 shares issued and outstanding at March 31, 2025 and June 30, 2024, respectively	19	11
Additional paid in capital	199,372,800	198,481,027
Accumulated other comprehensive loss, net of tax	(3,912,465)	(3,013,595)
Accumulated deficit	(169,463,046)	(177,977,071)
Total shareholders’ equity	25,997,308	17,490,372
Total liabilities and shareholders’ equity	$ 30,713,319	$ 27,649,093

Goodwill (Tables)

9 Months Ended

Mar. 31, 2025

Goodwill [Abstract]

Schedule of Carrying Value of Goodwill

The following table summarizes changes in the carrying value of goodwill for the nine months ended March 31, 2025 and 2024:


Carrying amount at June 30, 2024	$	8,690,018
Foreign currency exchange differences		(238,980	)
Carrying amount at March 31, 2025	$	8,451,038


Carrying amount at June 30, 2023	$	8,694,186
Foreign currency exchange differences		(68,082	)
Carrying amount at March 31, 2024	$	8,626,104

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Leases (Details) - Schedule of Effect of Lease Costs in our Condensed Consolidated Statements of Operations and Comprehensive (Income) Loss - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Operating lease costs
Research and development	$ 15,868	$ 15,218	$ 44,148	$ 45,902
General and administrative	15,921	16,945	49,727	50,859
Total	$ 31,789	$ 32,163	$ 93,875	$ 96,761

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2025	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2025	Mar. 31, 2024	Jun. 30, 2024
Cash flows from operating activities:
Net income (loss)	$ 11,262,161	$ (804,787)	$ (2,778,148)	$ (5,472,568)	$ 8,514,025	$ (12,805,140)	$ (15,500,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation					65,505	707,092
Depreciation and amortization expense					497,265	497,306
Non-cash rent expense					91,762	88,609
Change in fair value of accompanying warrant liability					(2,770,375)	0
Change in fair value of contingent consideration					66,937	584,299
Effect of foreign currency remeasurement					(633,539)	59,898
Changes in assets and liabilities:
Accounts receivable, non-trade					102,292	320,380
Prepaid insurance expense					437,868	164,273
Accounts payable					(1,498,326)	(858,952)
Accrued expenses and other current liabilities					(778,432)	(221,054)
Operating lease liabilities					(98,558)	(88,801)
Deferred tax liability					(201,803)	(104,380)
Contingent consideration					(133,080)
Other non-current liabilities					761	(13,517)
Net cash provided by (used in) operating activities					3,662,302	(11,669,987)
Cash flows from financing activities:
Proceeds from the sale of equity, net of issuance costs					823,601	7,987,228
Net cash provided by financing activities					823,601	7,987,228
Effect of exchange rate on changes on cash, cash equivalents, and restricted cash					(53,356)	4,607
Net increase (decrease) in cash, cash equivalents, and restricted cash					4,432,547	(3,678,152)
Cash, cash equivalents, and restricted cash, beginning of period		$ 12,686,935		$ 12,181,944	12,686,935	12,181,944	12,181,944
Cash, cash equivalents, and restricted cash, end of period	17,119,482		8,503,792		17,119,482	8,503,792	12,686,935
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	17,044,750		8,426,061		17,044,750	8,426,061	12,608,109
Restricted cash	74,732		77,731		74,732	77,731
Total cash, cash equivalents, and restricted cash	$ 17,119,482		$ 8,503,792		$ 17,119,482	$ 8,503,792	$ 12,686,935

Intangible Assets (Details) - Schedule of Intellectual Property Capitalized - USD ($)	9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance	$ 5,467,522
Carrying amount, Balance	4,970,474
Cancer Stem Cell Technology [Member]
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance	5,467,522	$ 6,130,253
Amortization expense	(497,048)	(497,048)
Carrying amount, Balance	$ 4,970,474	5,633,205
Kv1.3 Compounds [Member]
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance		1,057,835
Amortization expense		(1,057,835)
MultiCore [Member]
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance		865,664
Amortization expense		(865,664)
VDA Compounds [Member]
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance		1,561,248
Amortization expense		$ (1,561,248)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Net Income (Loss) per Share (Tables)

9 Months Ended

Mar. 31, 2025

Net Income (Loss) per Share [Abstract]

Schedule of Compilation of Diluted Earnings Per Share

The following table details the compilation of diluted earnings per share for the three and nine months ended March 31, 2025:


	Three months ended		Nine Months Ended
	March 31, 2025		March 31, 2025
Earnings per share - basic:
Net Income	$	11,262,161	$	8,514,025
Weighted average shares - basic		1,719,073		1,530,091
Net income per share - basic	$	6.55	$	5.56

Earnings per share - diluted:
Net Income	$	11,262,161	$	8,514,025
Less: effect of revaluation of accompanying warrant liability		—		(2,770,375	)
Net income plus assumed conversion of accompanying warrants	$	11,262,161	$	5,743,650
Weighted average shares - diluted		1,719,073		1,530,091
Net income per share - diluted	$	6.55	$	3.75

Schedule of Potential Shares of Common Stock

The following potential shares of common stock are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share.


	March 31,
	2025		2024
Options to purchase common stock		50,854		49,897
Warrants to purchase common stock		1,054,381		1,054,381

All share and earnings per share amounts presented above reflect the impact of the redomiciliation as if it had taken effect on July 1, 2023.

The Company and Basis of Presentation (Tables)

9 Months Ended

Mar. 31, 2025

The Company and Basis of Presentation [Abstract]

Schedule of Company’s Entity Structure at the End of the Reporting Period

Details of the Company’s entity structure at the end of the reporting period are as follows (post-redomiciliation):


Name	Entity	Country of Incorporation
Neuphoria Therapeutics Inc.	Parent	United States
Bionomics Limited	Subsidiary	Australia
Bionomics, Inc.	Subsidiary	United States

Intangible Assets

9 Months Ended

Mar. 31, 2025

Intangible Assets [Abstract]

Intangible Assets

Note 7. Intangible Assets

Intellectual Property

The acquired intellectual property relates to cancer stem cell technology and is carried at its cost on the date of acquisition, less accumulated amortization and impairment charges. There were no impairment indicators identified by the Company at March 31, 2025.


	Cancer Stem Cell Technology			Kv1.3 Compounds (1)			MultiCore (1)			VDA Compounds (1)
Carrying amount at June 30, 2024	$	5,467,522		$	-		$	-		$	-
Amortization expense		(497,048	)		-			-			-
Carrying amount at March 31, 2025	$	4,970,474		$	-		$	-		$	-

Carrying amount at June 30, 2023	$	6,130,253		$	1,057,835		$	865,664		$	1,561,248
Amortization expense		(497,048	)		(1,057,835	)		(865,664	)		(1,561,248	)
Carrying amount at March 31, 2024	$	5,633,205		$	-		$	-		$	-

(1) As of June 30, 2024, the KV1.3 compound, VDA compound, MultiCore technology intangible assets have been derecognized as no future economic benefits are expected from their use or disposition.

Acquired intellectual property with a finite life is recognized as an asset at cost and amortized on a straight line basis over its estimated useful life of 20 years. There is currently no internally generated intellectual property that has been capitalized.

Goodwill

9 Months Ended

Mar. 31, 2025

Goodwill [Abstract]

Goodwill

Note 6. Goodwill

The following table summarizes changes in the carrying value of goodwill for the nine months ended March 31, 2025 and 2024:


Carrying amount at June 30, 2024	$	8,690,018
Foreign currency exchange differences		(238,980	)
Carrying amount at March 31, 2025	$	8,451,038


Carrying amount at June 30, 2023	$	8,694,186
Foreign currency exchange differences		(68,082	)
Carrying amount at March 31, 2024	$	8,626,104

The Company reviews goodwill for impairment at the reporting unit on an annual basis during the fourth quarter, and when events or changes in circumstances indicate that a reduction in the carrying value may not be recoverable. The reporting unit has been identified as the drug development business unit. There were no impairment indicators identified by the Company at March 31, 2025.

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Revenue	$ 15,000,000		$ 15,662,715
Operating expenses:
Research and development	1,616,011	$ 1,198,546	5,253,953	$ 6,321,691
General and administrative	1,406,796	1,195,485	5,702,807	6,092,809
Total operating expenses	3,022,807	2,394,031	10,956,760	12,414,500
Income (loss) from operations	11,977,193	(2,394,031)	4,705,955	(12,414,500)
Other income (loss):
Interest income, net	12,741	52,615	79,452	193,770
Gain (loss) on foreign currency transactions	172,946	216,847	522,410	(148,296)
Research and development incentive award	(5,227)	271	301,006	94,981
Gain (loss) on fair value adjustments	(976,678)	(637,467)	2,703,438	(584,299)
Total other income (loss)	(796,218)	(367,734)	3,606,306	(443,844)
Income (loss) before income tax expense	11,180,975	(2,761,765)	8,312,261	(12,858,344)
Income tax benefit (expense)	81,186	(16,383)	201,764	53,204
Net Income (loss)	11,262,161	(2,778,148)	8,514,025	(12,805,140)
Other comprehensive loss:
Unrealized loss on foreign currency translation	(195,818)	(561,948)	(898,870)	(174,332)
Total other comprehensive loss:	(195,818)	(561,948)	(898,870)	(174,332)
Comprehensive income (loss)	$ 11,066,343	$ (3,340,096)	$ 7,615,155	$ (12,979,472)
Net income (loss) per share - basic	$ 6.55	$ (2.83)	$ 5.56	$ (15.2)
Weighted-average common shares outstanding - basic	1,719,073	981,040	1,530,091	842,431
Net income (loss) per share - diluted	$ 6.55	$ (2.83)	$ 3.75	$ (15.2)
Weighted-average common shares outstanding - diluted	1,719,073	981,040	1,530,091	842,431

Leases (Details) - Schedule of Operating and Finance Lease Including the Remaining Lease payments Through the end of the Expected Lease Term - USD ($)	Mar. 31, 2025	Jun. 30, 2024
Schedule of Operating and Finance Leases [Abstract]
Remainder of 2025	$ 30,612
2026	114,663
Remaining lease payments	145,275
Less: effect of discounting	(4,215)
Present value of operating lease liability	141,060
Current operating lease liabilities	121,738	$ 121,990
Non-current operating lease liabilities	$ 19,322	$ 117,628

Warrants (Details) - Schedule of Warrant Activity - ADS Warrants [Member]	9 Months Ended
	Mar. 31, 2025 $ / shares shares
Schedule of Warrant Activity [Line Items]
Number of ADS Warrants, Beginning Balance	1,579,086
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 7.92
Number of ADS Warrants, Exercised	(524,705)
Number of ADS Warrants, Ending Balance	1,054,381
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 11.88

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($)	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Income Taxes [Abstract]
Effective income tax rate	(0.73%)	(0.59%)	(2.43%)	(0.41%)
Income tax benefit (expense)	$ 81,186	$ (16,383)	$ 201,764	$ 53,204

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Warrants (Details) - Schedule of Classification, Expiration Date, and Exercise Price of Individual Warrants - 2024 accompanying ADS warrants [Member]	9 Months Ended
	Mar. 31, 2025 $ / shares shares
Schedule of Classification, Expiration Date, and Exercise Price of Individual Warrants [Line Items]
Number of ADS Warrants Outstanding \| shares	1,054,381
Exercise Price \| $ / shares	$ 11.88
Expiration Date	June 2029
Classification	Liability

Commitments and Contingencies (Details)	9 Months Ended
Commitments and Contingencies (Details)	Mar. 31, 2025 USD ($)
Dr. Spyros Papapetropoulos [Member]
Contingencies [Line Items]
Severance pay	$ 787,500

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2025	Mar. 31, 2024
Statement of Cash Flows [Abstract]
Net of issuance costs	$ 0.1	$ 0.1	$ 0.3	$ 0.5	$ 0.4	$ 0.9

Related Party Transactions

9 Months Ended

Mar. 31, 2025

Related Party Transactions

Note 15. Related Party Transactions

Danforth Advisors

In July 2021, we entered into a consulting agreement with Danforth Advisors LLC (“Danforth”) to provide consulting services to the Company. The Danforth agreement was amended in May 2023, and further amended in August 2023. Pursuant to the agreement, Danforth provides us with the Chief Financial Officer services of Mr. Cunningham, in addition to technical accounting and financial reporting services provided by other Danforth staff persons, in exchange for fees payable to Danforth. The Danforth agreement will continue until such time as either party has given notice of termination pursuant thereto with cause upon 30 days prior written notice to the other party; or without cause upon 60 days prior written notice.

WG Partners LLP

In December 2023, we executed an engagement letter with WG Partners LLP to provide financial advisory services to Bionomics, our predecessor entity. David Wilson, a director of Neuphoria, is the Chairman and Chief Executive Officer of WG Partners. Under the agreement, Neuphoria must pay WG Partners a monthly fee of $15,000 and commission of up to 5% of any fundraising proceeds attributable to this relationship. The agreement will continue until such time as a party gives 30 days prior written notice of termination to the other party. During the three and nine months ended March 31, 2025, we paid WG Partners $59,841 and $79,206, respectively, for its services under terms and conditions that are on an arms-length basis.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Accounts Receivable, Non-trade

9 Months Ended

Mar. 31, 2025

Accounts Receivable, Non-trade [Abstract]

Accounts Receivable, Non-trade

Note 4. Accounts Receivable, Non-trade

Accounts receivable, non-trade consist of the following:


	March 31,		June 30,
	2025		2024
Research and development incentives receivable	$	-	$	96,154
GST receivables		21,684		30,444
Interest receivable		2,908		286
Total accounts receivable, non-trade	$	24,592	$	126,884

Income Taxes

9 Months Ended

Mar. 31, 2025

Income Taxes [Abstract]

Income Taxes

Note 13. Income Taxes

For interim financial reporting, the Company estimates its annual effective tax rate based on the projected income for its entire fiscal year and records a provision or benefit for income taxes on a quarterly basis based on the estimated annual effective income tax rate. The Company recognized tax benefit of $81,186, or 0.73%, and tax expense of $16,383, or 0.59% three months ended March 31, 2025 and 2024, respectively. The Company recognized tax benefits of $201,764, or 2.43%, and $53,204, or 0.41%, for the nine months ended March 31, 2025 and 2024, respectively.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Goodwill (Details) - Schedule of Carrying Value of Goodwill - USD ($)	9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Schedule of Carrying Value of Goodwill [Abstract]
Carrying amount, Beginning	$ 8,690,018	$ 8,694,186
Foreign currency exchange differences	(238,980)	(68,082)
Carrying amount, Ending	$ 8,451,038	$ 8,626,104

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details